Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma

ClinicalTrials.gov ID: NCT00079417

Public ClinicalTrials.gov record NCT00079417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma. Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor from dividing so they stop growing or die. It is not yet known whether neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in treating intraocular retinoblastoma.

Study identification

NCT ID: NCT00079417
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Children's Oncology Group; Network
Enrollment: 28 participants

Conditions and interventions

Conditions

Intraocular Retinoblastoma

Interventions

Drug · Procedure · Radiation

Eligibility (public fields only)

Age range: Up to 5 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 26, 2005 (Actual)
Primary completion: Jan 1, 2010 (Actual)
Completion: Mar 31, 2017 (Actual)
Last update posted: Mar 13, 2023

2005 – 2017

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
Children's Hospital Los Angeles	Los Angeles	California	90027	—
Lurie Children's Hospital-Chicago	Chicago	Illinois	60611	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Wayne State University/Karmanos Cancer Institute	Detroit	Michigan	48201	—
Duke University Medical Center	Durham	North Carolina	27710	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
Children's Oncology Group	Philadelphia	Pennsylvania	19104	—
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston	Texas	77030	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00079417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 13, 2023 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00079417 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →